Literature DB >> 208970

Orofacial herpes simplex virus infection in hairless mice: latent virus in trigeminal ganglia after topical antiviral treatment.

R J Klein, A E Friedman-Kien, P B Yellin.   

Abstract

Inoculation of herpes simplex virus on the forehead and/or snout of hairless mice resulted in a significantly lower mortality rate than inoculation of the skin in the lumbosacral area. Latent herpes simplex virus infections were detected in all forehead-inoculated and in 90% of snout-inoculated mice. Phosphonoacetic acid was highly effective in preventing the development of skin lesions, and no latent infections were detected when phosphonoacetic acid ointment was applied 3 h after infection. Neither adenine arabinoside nor adenine arabinoside monophosphate prevented the establishment of latent infections in the trigeminal ganglia, although they protected the mice from the fatal outcome of the infection. The antibody response after adenine arabinoside or adenine arabinoside monophosphate treatment was similar to that observed in untreated animals, and it was six to eight times higher than in mice treated with phosphonoacetic acid. Mice without evidence of latent infection had, in general, lower serum antibody titers than those with latent infections in the ganglia. An analysis of the pathogenesis of herpes simplex virus infection in mice treated with adenine arabinoside showed that virus penetration into the nerve endings was delayed and that the amount of free virus in ganglionic homogenates was 10 to 100 times less than that for untreated mice.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 208970      PMCID: PMC421562          DOI: 10.1128/iai.20.1.130-135.1978

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  13 in total

1.  Immunological response restricts number of cells in sensory ganglia infected with herpes simplex virus.

Authors:  M A Walz; H Yamamoto; A L Notkins
Journal:  Nature       Date:  1976-12-09       Impact factor: 49.962

2.  Latent infection of the peripheral ANS with herpes simplex virus.

Authors:  R W Price; B J Katz; A L Notkins
Journal:  Nature       Date:  1975-10-23       Impact factor: 49.962

3.  Latent herpetic infections following experimental viraemia.

Authors:  M L Cook; J G Stevens
Journal:  J Gen Virol       Date:  1976-04       Impact factor: 3.891

4.  Efficacy of phosphonoacetic acid on herpes simplex virus infection of sensory ganglia.

Authors:  C R Wohlenberg; M A Walz; A L Notkins
Journal:  Infect Immun       Date:  1976-05       Impact factor: 3.441

5.  [On statistics of the plaque test].

Authors:  R J LORNEZ
Journal:  Arch Gesamte Virusforsch       Date:  1962

6.  Latent herpes simplex virus infections in sensory ganglia of mice after topical treatment with adenine arabinoside and adenine arabinoside monophosphate.

Authors:  R J Klein; A E Friedman-Kien
Journal:  Antimicrob Agents Chemother       Date:  1977-11       Impact factor: 5.191

7.  Latent ganglionic infection with herpes simplex virus types 1 and 2: viral reactivation in vivo after neurectomy.

Authors:  M A Walz; R W Price; A L Notkins
Journal:  Science       Date:  1974-06-14       Impact factor: 47.728

8.  Immune response and latent infection after topical treatment of herpes simplex virus infection in hairless mice.

Authors:  R J Klein; A E Friedman-Kien; A A Fondak; E Buimovici-Klein
Journal:  Infect Immun       Date:  1977-06       Impact factor: 3.441

9.  Protection from oral herpes simplex virus infection by a nucleic acid-free virus vaccine.

Authors:  E N Kitces; P S Morahan; J G Tew; B K Murray
Journal:  Infect Immun       Date:  1977-06       Impact factor: 3.441

10.  Latent herpes simplex virus in the central nervous system of rabbits and mice.

Authors:  F B Knotts; M L Cook; J G Stevens
Journal:  J Exp Med       Date:  1973-09-01       Impact factor: 14.307

View more
  15 in total

1.  Comparison of the effects of arabinosyladenine, arabinosylhypoxanthine, and arabinosyladenine 5'-monophosphate against herpes simplex virus, varicella-zoster virus, and cytomegalovirus with their effects on cellular deoxyribonucleic acid synthesis.

Authors:  J F Gephart; A M Lerner
Journal:  Antimicrob Agents Chemother       Date:  1981-01       Impact factor: 5.191

Review 2.  The pathogenesis of acute, latent and recurrent herpes simplex virus infections.

Authors:  R J Klein
Journal:  Arch Virol       Date:  1982       Impact factor: 2.574

3.  Effect of acyclovir on latent herpes simplex virus infections in trigeminal ganglia of mice.

Authors:  R J Klein; E DeStefano; A E Friedman-Kien; E Brady
Journal:  Antimicrob Agents Chemother       Date:  1981-05       Impact factor: 5.191

4.  Dissemination of herpes simplex virus in ganglia after footpad inoculation in neurectomized and non-neurectomized mice.

Authors:  R J Klein; E DeStefano
Journal:  Arch Virol       Date:  1983       Impact factor: 2.574

5.  Topical treatment of cutaneous herpes simplex virus infection in hairless mice with (E)-5-(2-bromovinyl)-2'-deoxyuridine and related compounds.

Authors:  E de Clercq
Journal:  Antimicrob Agents Chemother       Date:  1984-08       Impact factor: 5.191

6.  Latent infections of sensory ganglia as influenced by phosphonoformate treatment of herpes simplex virus-induced skin infections in hairless mice.

Authors:  R J Klein; E DeStefano; E Brady; A E Friedman-Kien
Journal:  Antimicrob Agents Chemother       Date:  1979-09       Impact factor: 5.191

7.  Latent herpes simplex virus infections in sensory ganglia of hairless mice prevented by acycloguanosine.

Authors:  R J Klein; A E Friedman-Kien; E DeStefano
Journal:  Antimicrob Agents Chemother       Date:  1979-05       Impact factor: 5.191

8.  Efficacies of gel formulations containing foscarnet, alone or combined with sodium lauryl sulfate, against establishment and reactivation of latent herpes simplex virus type 1.

Authors:  J Piret; J Lamontagne; A Désormeaux; M G Bergeron
Journal:  Antimicrob Agents Chemother       Date:  2001-04       Impact factor: 5.191

9.  Experimental skin infection with an acyclovir resistant herpes simplex virus mutant: response to antiviral treatment and protection against reinfection.

Authors:  R J Klein; E DeStefano; E Brady; A E Friedman-Kien
Journal:  Arch Virol       Date:  1980       Impact factor: 2.574

10.  Virus-specific antibodies in sera from patients with genital herpes simplex virus infection.

Authors:  H J Zweerink; L Corey
Journal:  Infect Immun       Date:  1982-08       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.